YU64100A - Postupak za sintetizovanje cox-2 inhibitora - Google Patents

Postupak za sintetizovanje cox-2 inhibitora

Info

Publication number
YU64100A
YU64100A YU64100A YU64100A YU64100A YU 64100 A YU64100 A YU 64100A YU 64100 A YU64100 A YU 64100A YU 64100 A YU64100 A YU 64100A YU 64100 A YU64100 A YU 64100A
Authority
YU
Yugoslavia
Prior art keywords
inhibitors
cox
synthesizing
synthesizing cox
cyclooxygenase
Prior art date
Application number
YU64100A
Other languages
English (en)
Inventor
Edward G. Corley
Ian W. Davies
Robert D. Larsen
Philip J. Pye
Kai Rossen
Original Assignee
Merck & Co.Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co.Inc. filed Critical Merck & Co.Inc.
Publication of YU64100A publication Critical patent/YU64100A/sh
Publication of RS49945B publication Critical patent/RS49945B/sr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/30—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups quaternised

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Pronalazak obuhvata postupak za izradu jedinjenja formule (I), koja su korisna u lečenju bolesti posredovanih ciklooksigenazom-2.[The invention encompasses a process for making compounds of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases.
YUP-641/00A 1998-04-24 1999-04-20 Postupak za sintetizovanje inhibitora cox-2 RS49945B (sr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8288898P 1998-04-24 1998-04-24
US8566898P 1998-05-15 1998-05-15

Publications (2)

Publication Number Publication Date
YU64100A true YU64100A (sh) 2002-11-15
RS49945B RS49945B (sr) 2008-09-29

Family

ID=26767964

Country Status (28)

Country Link
US (2) US6040319A (sh)
EP (1) EP1071745B1 (sh)
JP (2) JP3325264B2 (sh)
KR (1) KR100414998B1 (sh)
CN (1) CN1178658C (sh)
AR (1) AR015279A1 (sh)
AT (1) ATE272613T1 (sh)
AU (1) AU759469B2 (sh)
BR (2) BR9909844B1 (sh)
CA (1) CA2329193C (sh)
CZ (1) CZ292515B6 (sh)
DE (1) DE69919151T2 (sh)
DK (1) DK1071745T3 (sh)
EA (1) EA002975B1 (sh)
ES (1) ES2226378T3 (sh)
HK (1) HK1031399A1 (sh)
HR (1) HRP20000722B1 (sh)
HU (1) HU227627B1 (sh)
IL (2) IL139127A0 (sh)
NZ (1) NZ507597A (sh)
PL (1) PL193248B1 (sh)
PT (1) PT1071745E (sh)
RS (1) RS49945B (sh)
SI (1) SI1071745T1 (sh)
SK (1) SK284805B6 (sh)
TW (1) TW474934B (sh)
UA (1) UA57143C2 (sh)
WO (1) WO1999055830A2 (sh)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
KR100446324B1 (ko) 1999-01-14 2004-08-30 론자 아게 1-(6-메틸피리딘-3-일)-2-[4-(메틸술포닐)페닐]에타논 및이의 제조 방법
DK1159270T3 (da) * 1999-01-14 2004-02-23 Lonza Ag Fremgangsmåde til fremstilling af 1-(6-methylpyridin-3-yl)-2-[(4-(methylsulfonyl)phenyl]ethanon
JP2001115963A (ja) 1999-10-13 2001-04-27 Daikin Ind Ltd 圧縮機
EP1248618B1 (en) * 1999-11-29 2006-03-22 Merck Frosst Canada Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- 2,3']bipyridinyl
US6858631B1 (en) 1999-11-29 2005-02-22 Merck & Co., Inc. Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
KR100793668B1 (ko) * 1999-12-08 2008-01-10 파마시아 코포레이션 강화된 생체이용률을 지닌 고체상 형태의 셀레콕시브
JP2001261653A (ja) * 2000-03-17 2001-09-26 Sankio Chemical Co Ltd ピリジン誘導体の合成法
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6800647B2 (en) 2000-05-26 2004-10-05 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PE20020146A1 (es) * 2000-07-13 2002-03-31 Upjohn Co Formulacion oftalmica que comprende un inhibidor de ciclooxigenasa-2 (cox-2)
WO2002005848A2 (en) * 2000-07-13 2002-01-24 Pharmacia Corporation Use of cox-2 inhibitors in the treatment and prevention of ocular cox-2 mediated disorders
US7115565B2 (en) * 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US7695736B2 (en) 2001-04-03 2010-04-13 Pfizer Inc. Reconstitutable parenteral composition
EP1423114A4 (en) * 2001-05-04 2006-05-17 Merck & Co Inc METHOD AND COMPOSITIONS FOR TREATING MIGRAINE
UA80682C2 (en) * 2001-08-06 2007-10-25 Pharmacia Corp Orally deliverable stabilized oral suspension formulation and process for the incresaing physical stability of thixotropic pharmaceutical composition
JP4700916B2 (ja) 2004-02-02 2011-06-15 富士フイルムファインケミカルズ株式会社 ピリジン誘導体の製造方法
US7271383B2 (en) * 2004-08-11 2007-09-18 Lexmark International, Inc. Scanning system with feedback for a MEMS oscillating scanner
EP1784179A4 (en) 2004-08-24 2010-03-31 Merck Sharp & Dohme COMBINATION THERAPY FOR THE TREATMENT OF CYCLOOXYGENASE-2-MEDIATED DISEASES OR CONDITIONS IN PATIENTS WITH RISK TO THROMBOTIC CARDIOVASCULAR EVENTS
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
PT2479166E (pt) 2009-02-27 2014-11-28 Cadila Healthcare Ltd Processo para a preparação de etoricoxib
EP2582690B1 (en) 2010-06-16 2018-07-25 Glenmark Generics Limited Process for preparation of 2, 3-diaryl-5-substituted pyridines and their intermediates
WO2012066570A2 (en) 2010-11-15 2012-05-24 Virdev Intermediates Pvt. Ltd. A process for cyclooxygenase-2 selective inhibitor
ITMI20110362A1 (it) * 2011-03-09 2012-09-10 F I S Fabbrica Italiana Sint P A Procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
EA023286B1 (ru) 2011-05-27 2016-05-31 ФАРМА ДжРС, Д.О.О. Способ получения полиморфной формы i эторикоксиба
ITMI20111455A1 (it) 2011-07-29 2013-01-30 Italiana Sint Spa Nuovo procedimento per la preparazione di 1-(6-metilpiridin-3-il)-2-[4-(metilsolfonil)fenil]etanone, un intermedio dell'etoricoxib.
CN103204803A (zh) 2012-01-13 2013-07-17 阿尔弗雷德·E·蒂芬巴赫尔有限责任两合公司 用于合成依托考昔的方法
ITMI20120394A1 (it) * 2012-03-14 2013-09-15 Zach System Spa Processo di sintesi di un chetosolfone derivato
EP2831045A2 (en) 2012-03-30 2015-02-04 Mylan Laboratories, Limited An improved process for the preparation of etoricoxib
GR1007973B (el) * 2012-06-26 2013-09-12 Φαρματεν Αβεε, Νεα ν-οξοιμινο παραγωγα ως ενδιαμεσα μιας βελτιωμενης μεθοδου παρασκευης 2,3-διαρυλο-5-υποκατεστημενων πυριδινων
EP2887924B1 (en) 2012-08-27 2017-03-29 Cadila Healthcare Limited Pharmaceutical compositions of etoricoxib
ITVI20130014A1 (it) 2013-01-22 2014-07-23 Italiana Sint Spa Procedimento molto efficiente per preparare un intermedio di etoricoxib
WO2014114352A1 (en) * 2013-01-25 2014-07-31 Synthon Bv Process for making etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
WO2016149126A1 (en) 2015-03-13 2016-09-22 The Board Of Trustees Of The Leland Stanford Junior University Ltb4 inhibition to prevent and treat human lymphedema
CN104817473A (zh) * 2015-03-27 2015-08-05 南京大学 1-二甲氨基-3-二甲亚胺基-2-氯丙烯高氯酸盐在制备依托考昔中的应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA988522A (en) * 1972-05-05 1976-05-04 Haydn W.R. Williams 1,8-naphthyridine compounds
DE3842062A1 (de) * 1988-12-14 1990-06-28 Hoechst Ag Explosionssichere 1-dimethylamino-3-dimethylimino-2-arylpropen-1-salze, verfahren zu ihrer herstellung und ihre verwendung
SI0912518T1 (en) * 1996-07-18 2003-12-31 Merck Frosst Canada & Co. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors

Also Published As

Publication number Publication date
DE69919151T2 (de) 2005-07-28
AR015279A1 (es) 2001-04-18
NZ507597A (en) 2004-02-27
IL139127A (en) 2006-07-05
KR20010042941A (ko) 2001-05-25
HRP20000722A2 (en) 2001-06-30
PT1071745E (pt) 2004-11-30
EA200001102A1 (ru) 2001-04-23
WO1999055830A3 (en) 1999-12-29
IL139127A0 (en) 2001-11-25
CZ20003940A3 (en) 2001-06-13
CN1306425A (zh) 2001-08-01
AU759469B2 (en) 2003-04-17
RS49945B (sr) 2008-09-29
HUP0101407A2 (hu) 2001-09-28
UA57143C2 (uk) 2003-06-16
BRPI9917739B1 (pt) 2016-05-03
JP2002513035A (ja) 2002-05-08
HU227627B1 (en) 2011-10-28
US6040319A (en) 2000-03-21
EA002975B1 (ru) 2002-12-26
CN1178658C (zh) 2004-12-08
PL193248B1 (pl) 2007-01-31
CA2329193C (en) 2007-01-23
CA2329193A1 (en) 1999-11-04
PL344108A1 (en) 2001-09-24
BRPI9917739B8 (pt) 2021-05-25
SI1071745T1 (en) 2004-10-31
DE69919151D1 (de) 2004-09-09
SK284805B6 (sk) 2005-11-03
BR9909844A (pt) 2001-04-03
HRP20000722B1 (en) 2009-07-31
EP1071745A4 (en) 2002-05-15
JP2003040852A (ja) 2003-02-13
JP3834263B2 (ja) 2006-10-18
US6252116B1 (en) 2001-06-26
ES2226378T3 (es) 2005-03-16
TW474934B (en) 2002-02-01
KR100414998B1 (ko) 2004-01-13
HK1031399A1 (en) 2001-06-15
JP3325264B2 (ja) 2002-09-17
BR9909844B1 (pt) 2010-10-19
HUP0101407A3 (en) 2002-12-28
EP1071745A2 (en) 2001-01-31
EP1071745B1 (en) 2004-08-04
ATE272613T1 (de) 2004-08-15
AU3655799A (en) 1999-11-16
SK15892000A3 (sk) 2001-07-10
WO1999055830A2 (en) 1999-11-04
DK1071745T3 (da) 2004-11-29
CZ292515B6 (cs) 2003-10-15

Similar Documents

Publication Publication Date Title
YU64100A (sh) Postupak za sintetizovanje cox-2 inhibitora
WO1999015503A3 (en) Process for making diaryl pyridines useful as cox-2 inhibitors
LU91145I9 (sh)
UA49809C2 (uk) Спосіб одержання фенільних гетероциклів, які використовуються як інгібітори цог-2, а також сполуки, одержані цим способом
ZA944501B (en) Phenyl heterocycles as cox-2 inhibitors
ATE212343T1 (de) 3,4-diaryl-2-hydroxy-2,5-dihydrofurane als wirkstoffvorstufen von cox-2 inhibitoren
CA2258048A1 (en) Process of preparing phenyl heterocycles useful as cox-2 inhibitors
ZA200404752B (en) 6-aminomorphinane derivatives method for the production and use thereof
YU89402A (sh) 5-hloro-3-(4-metansulfonilfenil)-6'-metil-/2,3'/bipiridinil u čistom kristalnom obliku i postupak sinteze
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
PL336298A1 (en) Method of obtaining 2-aryl-3-aryl-halopyridines useful as cox-2 inhibitors
MXPA04003755A (es) Endoprotesis vasculares.
DE69715173D1 (en) Bisarylcyclobutenderivate als cyclooxygenasehemmer
ATE193526T1 (de) Alkylierte styrole als prodrugs zu cox-2- inhibitoren
PL330227A1 (en) Method of obtaining phenylheterocyclic compounds suitable as cox-2 inhibitors
EE9800230A (et) Difenüülstilbeenid kui COX-2 inhibiitorite eelravimid
ZA200400824B (en) Pyridin-2-yl-methlyamine derivatives for treating opioid dependence.